Angelini Ventures co-leads alongside Invivo Partners with participation from Innovestor’s Life Science Fund and other existing investors Financing will support clinical development of Neumirna‘s lead asset NMT.001, a potential disease-modifying Antisense Oligonucleotide (ASO) therapy for drug-resistant epilepsy, as well as expand its R&D capabilities and scale its pioneering drug discovery platform Angelini Venture’s investment in Neumirna marks its 5th in the field of neurological disorders and

Successfully dosed 6 patients in safety run-in segment, now accelerating enrollment Positive data from first four patients announced December 2024 NXC-201 is the only one-time CAR-T therapy in development for AL Amyloidosis Next program update Q1 2025 AL Amyloidosis is a life-threatening disorder of plasma cells in the bone marrow affecting ~33,000 patients in the U.S. Jan. 07, 2025 -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”), a clinical-stage biopharma

January 8, 2025 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, and ESTEVE, an international specialty pharma company with a focus on highly specialized treatments that address significant unmet medical needs, today announced the signing of the Distribution and Licence Agreement renewal in Germany for AKYNZEO® (combination of netupitant-palonoset

• Second regulatory designation for Restem-L, a lead ULSC program, following the recent Orphan Drug Designation • Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use within 6 months in Idiopathic Inflammatory Myopathy (IIM) • Company is on track to initiate IIMPACT, a potentially registrational Phase 2/3 clinical trial in IIM in Q1 2025 Jan. 07, 2025 -- RESTEM – a clinical-stage biotechnology company that develops off

Jan. 06, 2025 -- Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is thrilled to announce a groundbreaking partnership with Stephen Gould, marking a monumental step forward in the manufacturing and distribution of CBIH’s advanced medical product line. This collaboration represents a shared commitment to excellence and innovation in the healthcare industry. Stephen Gould, a company with a remarkable presence in over 40 locations across six countries, brings an extraordinary legacy of

Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile Conducted positive end of Phase 2 FDA meeting; Phase 3 program expected to be initiated in Q1 2025 Topline Phase 3 data expected in second half of 2026; cash runway expected through mid-2027 Conference call to review unmet need in TED, new Phase 2 data and Phase 3 program design to be held today, January

Jan. 06, 2025 -- LB Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia, today announced that Heather Turner, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare conference in San Francisco on Monday, January 13, 2025 at 1:30 p.m. PT. LB-102 is a once-daily, orally administered, small molecule being developed as a potential first-in-class benzamide antipsy

Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 pathology slides and decades of longitudinal drug response data Data provides a critical pathway to progress AI using the high-speed computing power provided through collaboration with Nebul Combines Predictive Oncology’s AI-driven multi-omic drug discovery platform with Renovaro’s AI Cube multi-omic artificial intelligence to advance both cancer diagnostics and early drug disco

Once-daily VYN201 gel being evaluated in subjects with nonsegmental vitiligo Top-line data from the 24-week double-blind portion of the trial expected in mid-2025 “Repibresib” approved as the non-proprietary name for VYN201 by USAN Jan. 06, 2025 -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today annou

Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2 mg in other key global regions Jan. 06, 2025 -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that ARS Pharma has filed for approval of neffy® (epinephrine nasal sp